Hasil Pencarian  ::  Simpan CSV :: Kembali

"ABSTRAKPendahuluan : Docetaxel telah menunjukkan efek dalam pengobatan CRPC biladigunakan sebagai monoterapi atau dalam kombinasi dengan kemoterapi lainnya.Banyak penelitian telah menunjukkan korelasi penurunan Prostate Specific Antigen PSA dengan kesintasan pasien CRPC yang mendapatkan terapi Docetaxel.Penelitian-penelitian sebelumnya juga menyatakan adanya korelasi antara volumeprostat, Gleason Score, dan insiden metastasis dengan nilai PSA. Penelitian inibertujuan untuk menganalisis hubungan antara volume prostat, Gleason Score, danada tidaknya metastasis terhadap penurunan PSA sebagai prediktor respon padapasien CRPC yang mendapatkan Docetaxel.Metode : Penelitian analitik retrospektif dengan mengunakan data rekam medisRumah Sakit Umum H. Adam Malik Medan yang dilaksanakan pada periode 1Januari 2016-31 Juli 2016. Populasi dan sampel dalam penelitian ini adalah seluruhpasien dengan penderita CRPC yang telah menjalani kemoterapi Docetaxelsebanyak 10 siklus. Pasien yang memenuhi kriteria inklusi, dipaparkan denganvariabel independen Taksiran Besar Prostat, Skor Gleason, Status Metastase danvariabel dependen perubahan PSA .Hasil : Sebanyak 8 pasien yang memenuhi kriteria inklusi yang berusia rata-rata 65tahun dengan taksiran berat prostat 38,6 gram dengan skor gleason ge; 7 sebanyak 6orang 75 sedangkan

---

ABSTRACTIntroduction Docetaxel has shown efficacy in CRPC treatment as monotherapy or combination therapy. Previous research showed a correlation between prostat volume, Gleason score, and metastases with PSA value. This study aimed toanalyze the correlation between prostat volume, gleason score, and metastases withPSA value decrement as a response predictor in CRPC patients who receiveDocetaxel.Methods This is a retrospective analytic research, using data in medical recordsin RSU H. Adam Malik Medan, conducted on January 1 July 31 2016. Populationand samples in this research are patients with CRPC who already received 10 cyclesof Docetaxel chemotherapy. Patients that fulfilled the inclusion criteria areanalyzed with dependent and independent variables estimated prostate volume,Gleason Score, and metastatic status . Results Total of 8 patients who fulfilled inclusion criteria were averagely 65 yearsold, estimated prostate weight of 38.6 gram, and 6 people had Gleason score ge 7 75 and 2 people had Gleason score "

"Latar Belakang: Paru merupakan salah satu organ tersering ditemukan lesi metastasis. Reseksi sublobar dapat berupa reseksi baji atau segmentektomi. Saat ini belum ada telaah sistematik atau metaanalisis yang membandingkan keduaya. Tujuan kajian ini adalah membuktikan segmentektomi merupakan metode metastasektomi dengan kesintasan yang lebih baik. Metode: Tinjauan sistematik ini dilakukan dengan menerapkan kaidah yang disusun dalam PRISMA-P. Pencarian terhadap artikel yang sesuai dilakukan pada database PubMed, EBSCO, dan EMBASE. Data kemudian dilakukan telaah kritis dengan piranti ROBINS-1. Data yang diekstraksi kemudian diolah lebih lanjut dengan bantuan piranti lunak Review Manager 5.4. Hasil: Lima artikel diikut sertakan dalam tinjauan sistematik ini. Kelima artikel tersebut melaporkan hasil penelitian dengan desain kohort retrospektif. Total subjek penelitian yang diikutkan dalam analisis akhir adalah 1011. Analisis forest plot bahwa segmentektomi memiliki kesintasan lima tahun yang terbaik (RR:0,72; 95% CI: 0,59-0,88). Sedangkan analisis subgrup yang dilakukan menemukan bahwa segmentektomi memiliki kesintasan terbaik dibandingkan dengan reseksi baji pada tumor kolorektal (RR: 0,69; 95% IK: 0,55-0,85) tetapi tidak pada jenis lesi primer sarkoma (RR: 0,98; 95% IK : 0,67-1,42). Kesimpulan: Subjek penelitian dengan lesi metastasis paru dari keganasan kolorektal yang menjalani metastasektomi secara segmentektomi memiliki kesintasan yang terbaik jika dibandingkan dengan yang menjalani metastasektomi dengan reseksi baji.

---

Background: The lung is the organ where metastatic lesions are most frequently found. Sublobar resection can be wedge resection or segmentectomy. There is currently no systematic review or meta-analysis that compares the two. Aim of the study is to prove that segmentecomy is better than wedge resection in terms of survival.

Methods: This systematic review is done by applying the principle in PRISMA-P. Literature searching methods is done in PubMed, EBSCO, and EMBASE. Data then reviewed systematically with ROBINS-1. The extracted data were analyzed further by using Review Manager 5.4 Software.

Results: Five articles were included in this systematic review. The five articles report the results of a study with a retrospective cohort design. The total number of patients included in the final analysis was 1011. Forest plot analysis showed that segmentectomy had a best five-year survival (RR: 0.72; 95% CI: 0.59-0.88). Meanwhile, the subgroup analysis found that segmentectomy had best survival compared to wedge resection in colorectal tumors (RR: 0.69; 95% CI: 0.55-0.85) but not of sarcoma (RR: 0.98; 95% CI: 0.67-1.42).

Conclusion: Patients with lung metastases from colorectal malignancies who underwent metastasectomy by segmentectomy had the best survival compared to those who underwent metastasectomy by wedge resection."

"Latar belakang: Insidens metastasis otak lebih tinggi dibanding tumor primer otak dan berisiko menimbulkan kematian dengan penyebab terbanyak berasal dari kanker paru (36,5%) di RSUPN Cipto Mangunkusumo (RSCM). Keterlambatan diagnosis berisiko menyebabkan herniasi otak, sehingga terjadi kecacatan dan kematian. Dibutuhkan data mengenai durasi penegakan diagnosis di RSCM.Metode penelitian: Penelitian ini merupakan studi deskriptif analitik dengan rancangan kohort retrospktif untuk mengetahui kesesuaian antara durasi penegakan diagnosis tumor otak metastasis akibat kanker paru dengan pedoman praktik klinis (durasi ≤2 minggu). Subjek merupakan pasien rawat inap di RSCM pada Januari 2019 s/d Desember 2021.Hasil: Terdapat 12 subjek (30%) dapat ditegakkan dalam waktu ≤2 minggu dengan  median durasi 18,5 hari (IQR (12-34 hari). Selain itu didapatkan durasi 7 hari (IQR 4-11 hari) untuk sampai didapatkannya massa di paru,  durasi 8 hari (IQR 4.5-13 hari) sampai dilakukannya biopsi, dan 6 hari (IQR 3.5-7 hari) sampai keluarnya hasil patologi anatomi. Tidak terdapat hubungan yang bermakna secara statistik antara variabel yang dinilai dengan durasi penegakan diagnosis ≤2 minggu (14 hari).Kesimpulan: Hanya 30% subjek dengan durasi yang sesuai dengan panduan praktik klinis di RSCM. Dibutuhkan diseminasi hasil dan kolaborasi antar bagian agar penegakan diagnosis lebih cepat.

---

Background: Incidence of brain metastases is higher than primary brain tumors, with lung cancer as common etiology (36.5%) at Cipto Mangunkusumo General Hospital (RSCM). Delay in diagnosis can cause brain herniation, resulting in disability and death. Data is needed regarding the duration of diagnosis in RSCM.

Method: This is a descriptive analytic study with a retrospective cohort design to determine the conformity between the duration of diagnosis of metastatic brain tumors due to lung cancer in daily clinical practice with clinical practice guidelines (duration 2 weeks). Subjects were inpatients at RSCM from January 2019 to December 2021

Results: There were 12 subjects (30%) who could be diagnosed within 2 weeks with a median duration of 18.5 days (IQR (12-34 days). Duration of 7 days (IQR 4-11 days) to obtain a lung mass, 8 days (IQR 4.5-13 days) until a biopsy was performed, and 6 days (IQR 3.5-7 days) until anatomic pathology results were released. There is no statistically significant relationship between the variables assessed and the duration of diagnosis 2 weeks.

Conclusion: Only 30% of subjects with the duration matched the clinical practice guidelines at RSCM. Dissemination of results and collaboration between departments is needed to make diagnosis faster."

"ABSTRAKPenderita metastase kelenjar getah bening leher yang tumor primernya tidak diketahui, umumnya datang untuk pengobatan radiasi sudah berada dalam tingkat klinis yang lanjut.Pengamatan terhadap respons radiasi pada kasus metastase kelenjar getah bening leher yang tumor primernya tidak diketahui ini membuktikan prognosa yang relatif baik. Dosis yang diberikan selai untuk eradikasi metastase pada kelenjar, juga untuk tumor primerya. Diperlukan pengamatan yang lebih lama dan pendataan ukuran kelenjar yang teliti pasca radiasi.Penggolongan tingkat klinis dirasakan tidak memadai karena tidak mencantumkan ukuran dan jumlah kelenjar"

"Kanker orofaring termasuk kedalam kanker kepala dan leher, dimana kanker terjadi di bagian tengah tenggorokan yang berada tepat di belakang rongga mulut. Pada stadium lanjut, kanker ini dapat menyebar ke organ yang jauh. Tiga puluh dari 772 penderita kanker ini (3,9%) memiliki bukti klinis adanya metastase sel kanker ke area tulang belakan (Suzuki et al, 2020). Penyebaran sel kanker ke daerah tulang sering disebut dengan penyakit metastasis tulang atau Metastatic Bone Disease (MBD). Adanya fraktur patologis di segmen vetebra merupakan salah satu tanda adanya penyebaran kanker ke daerah spinal. Saraf spinalis pun berisiko mengalami cedera karena berada tepat dibawah dan di sepanjang tulang belakang. Pada kasus ini pasien mengeluh kedua kakinya tidak mampu digerakkan dan tidak dapat mengontrol BAK. Hal ini menunjukan adanya cedera neurologis di bagian saraf spinalis pasien. Tatalaksana medis yang sudah dilakukan adalah berupa dekompresi dan stabilisasi posterior di daerah thorakal dan lumbal. Pemasangan implan tersebut tidak serta merta mengembalikan fungsi sensorik dan motorik pasien, sehingga diperlukan adanya latihan untuk mempertahankan bagian tubuh yang terdampak. Selama 5 hari penulis melakukan interveni ROM untuk mempertahankan kekuatan otot dan fleksibilitas sendi pasien. Penulis juga melibatkan keluarga dalam latihan yang dilakukan 2 kali sehari selama 30 menit. Hasil yang didapat adalah kekuatan motorik ekstremitas atas 5555/5555 dan motorik ekstremitas bawah 1111/1111. Jari-jari kaki kiri dapat bergerak minimal. Kontraksi otot pasien makin teraba dan terlihat walau sedikit. Tidak ada spastisitas pada otot, kontraktur sendi maupun deformitas.

---

Oropharyngeal cancer is included in head and neck cancer, where cancer occurs in the middle of the throat which is right behind the oral cavity. In advanced stages, this cancer can spread to distant organs. Thirty of the 772 cancer sufferers (3.9%) had clinical evidence of cancer cell metastases to the spine area (Suzuki et al, 2020). The spread of cancer cells to the bone area is often called metastatic bone disease (MBD). The presence of a pathological fracture in the spinal segment is a sign of the spread of cancer to the spinal area. The spinal nerves are also at risk of injury because they are located directly below and along the spine. In this case the patient complained that he could not move his legs and could not control his urination. This indicates a neurological injury to the patient's spinal cord. The medical treatment that has been carried out is in the form of decompression and posterior stabilization in the thoracic and lumbar areas. Installation of these implants does not immediately restore the patient's sensory and motor function, so training is needed to maintain the affected body parts. For 5 days the author carried out ROM intervention to maintain the patient's muscle strength and joint flexibility. The author also involves the family in exercises which are carried out twice a day for 30 minutes. The results obtained were upper extremity motor strength 5555/5555 and lower extremity motor strength 1111/1111. The toes of the left foot can move minimally. The patient's muscle contractions become more palpable and visible, although slightly. There is no spasticity in muscles, joint contractures or deformities."

"ABSTRAKTujuan: Mengetahui batasan nilai PSA untuk memprediksi adanya metastasis tulang pada pasien kanker prostat di RS Sardjito. Metode: Penelitian retrospektif, dengan mengumpulkan rekam medis pasien kanker prostat telah dilakukan bone scintigraphy di RS Sardjito tahun 2006 - 2011.Hasil: Dari 83 pasien kanker prostat yang telah dilakukan bone scintigraphy, terdapat 55 pasien (66%) mengalami metastasis tulang dan terdapat 28 pasien (34 %) yang tidak mengalami metastasis tulang. Dari 55 pasien yang mengalami metastasis tulang, terdapat 11 pasien (20 %) dengan PSA kurang dari 20 ng/ml dan terdapat 44 pasien (80 %) yang memiliki PSA lebih dari 20 ng/ml. Cut-off point PSA 17.65 ng/ml memiliki sensitivitas terbesar yaitu 85.5% dan spesifisitas 53.6%.Kesimpulan: Pemeriksaan bone scintigraphy dianjurkan pada pasien dengan PSA > 17.65 ng/ml, sedangkan pada pasien dengan PSA < 17.65 dianjurkan pada pasien dengan gejala klinis nyeri tulang.

---

ABSTRACTObjective: Prostate cancer shows a strong predilection to spread to the bones, with bone metastases identified at autopsy in up to 90 % of patients dying from prostate cancer. Serum prostate specific antigen (PSA) concentration has been widely applied as a biomarker to diagnose and monitor prostate cancer. Technetium-99m methylene diphosphate (Tc—99m MDP) whole body bone scintigraphy is currently a well-accepted diagnostic procedure for bone metastasis in malignancy. The aim of this study was to establish a useful serum PSA cut-off value to predict the presence of bone metastasis in men with prostate cancer. Material and Methods: Consecutive male patients diagnosed with prostate cancer were retrospectively analyzed. All of the subjects had received Tc-99m MDP whole body bone scintigraphy and had their serum PSA concentration measured at Sardjito Hospital, Yogyakarta. The proper cut-off value was established based on statistical analysis in order to predict the possibility of bone metastasis among prostate cancer patients.Results: In total, 83 consecutive male patients with prostate cancer were enrolled, and 55 patients (66 %) were confirmed by scintigraphic findings to have bone metastases. A serum PSA concentration of 17,65 ng/ml gave the best sensitivity (78,33 %) and specificity (65,21 %). The positive predictive value, negative predictive value were 85,45 % and 53,57 %, respectively (p<0,05).Conclusion: A cut-off value of 17,65 ng/ml appears to be an appropriate benchmark for stratifying metastatic bone disease in prostate cancer patients at Sardjito Hospital, Yogyakarta, such that if a patient with newly diagnosed prostate cancer and without any skeletal symptoms has a serum PSA concentration of less than 17,65 ng/ml,we suggest that they would not need to undergo bone scintigraphy."

"[ABSTRAKTujuan: Insiden kanker prostat secara global terus meningkat. Meskipun dapat dilakukan deteksi dini kanker prostat, perlu dipahami bahwa progresivitas penyakit ? menjadi metastasis ? berbeda untuk setiap pasien. Penelitian ini bertujuan untuk mengamati aspek-aspek yang mungkin berperan sebagai faktor prediktif metastasis pada kanker prostat tidak terpalpasi.Material dan Metode: Data dikumpulkan dari Rumah Sakit Umum Pusat Nasional Cipto Mangunkusumo dan Rumah Sakit Pusat Kanker Nasional Dharmais sejak tahun 1995-2013. Pasien dengan kanker prostat tidak terpalpasi kemudian dibagi menjadi dua kelompok: dengan metastasis dan tanpa metastasis. Usia, volume prostat, nilai prostate-spesific antigen (PSA), Gleason score sum group, stadium tumor, Karnofsky performance score (KPS), kadar hemoglobin, dan kadar kreatinin serum merupakan faktor yang dianalisis dalam penelitian ini. Data dianalisis menggunakan analisis bivariat dan uji regresi logistik. Hanya pasien dengan data lengkap yang dimasukkan dalam penelitian ini.Hasil: Didapatkan 91 pasien dengan data lengkap, 59 pasien (64,83%) tanpa metastasis dan 32 pasien (35,16%) dengan metastasis. Terdapat perbedaan statistik yang signifikan antara kelompok tanpa metastasis dan kelompok dengan metastasis, yakni untuk PSA (13.7ng / mL vs 71.5ng / mL; p = 0,001), kadar hemoglobin (13,60 g / dL vs 12,25 g / dL; p = 0,002), dan KPS (90 vs 90 ; p = 0,004). Perbedaan yang signifikan secara statistik juga didapatkan pada kelompok GSS (35 dan 24 pada kelompok tanpa metastasis vs 12 dan 20 pada kelompok dengan metastasis; p = 0,047). Usia, volume prostat, stadium tumor, dan kadar kreatinin antara kedua kelompok tidak memiliki perbedaan signifikan secara statistik (p> 0,05). Nilai pretreatment PSA adalah satu-satunya faktor prediktif untuk metastasis dengan odds ratio 1.014 (95% CI, 1,005-1,022; p = 0,002).Kesimpulan: Sebagian besar pasien kanker prostat tidak terpalpasi terdeteksi pertama kali tanpa metastasis. Nilai pretreatment PSA yang diperoleh pada kunjungan awal pasien dapat digunakan sebagai faktor prediktif metastasis di masa depan.

---

ABSTRACTObjective: Prostate cancer incident is globally increasing. Despite early detection of prostate cancer, the progressivity of the disease itself toward metastatic disease remains different for each patient. The purpose of this study is to observe aspects that may have roles as predictive factors for metastasis in nonpalpable prostate cancer.Materials and Methods: Data was collected from National Hospital Cipto Mangunkusumo and Dharmais National Cancer Center Hospital from 1995-2013. Patients with nonpalpable prostate cancer then divided into two groups: metastasis-free group and metastasis group. Age, prostate volume, pretreatment Prostate-specific antigen (PSA) value, Gleason score sum group, tumor stadium, Karnofsky performance score (KPS), hemoglobin level, and serum creatinine level were factors that were analyzed in the study. The data was analyzed using bivariate analysis and logistic regression test. Only patients with complete data are included in the study.Results: There are 91 patients with complete data, 59 patients (64.83%) were patients without metastasis and 32 patients (35.16%) were with metastasis. There was significant statistical difference between no metastasis group with metastasis group for PSA (13.7ng/mL vs71.5ng/mL; p = 0.001), hemoglobin level (13.60 g/dL vs 12.25 g/dL; p = 0.002), and KPS (90vs90; p = 0.004). There was also significant statistical difference in GSS groups (35 and 24 in metastasis-free group vs 12 and 20 in metastasis group; p = 0.047). Age, prostate volume, tumor stadium, and creatinine level had no statistical difference between the two groups (p > 0.05). Pretreatment PSA value was the only predictive factor for metastasis with odds ratio 1.014 (95% CI, 1.005 to 1.022; p = 0.002).Conclusion: Most nonpalpable prostate cancer patients are first detected without metastasis. Pretreatment PSA value that was obtained at their initial visit might be used as predictive factor for metastasis for them in the future.;Objective: Prostate cancer incident is globally increasing. Despite early detection of prostate cancer, the progressivity of the disease itself toward metastatic disease remains different for each patient. The purpose of this study is to observe aspects that may have roles as predictive factors for metastasis in nonpalpable prostate cancer.Materials and Methods: Data was collected from National Hospital Cipto Mangunkusumo and Dharmais National Cancer Center Hospital from 1995-2013. Patients with nonpalpable prostate cancer then divided into two groups: metastasis-free group and metastasis group. Age, prostate volume, pretreatment Prostate-specific antigen (PSA) value, Gleason score sum group, tumor stadium, Karnofsky performance score (KPS), hemoglobin level, and serum creatinine level were factors that were analyzed in the study. The data was analyzed using bivariate analysis and logistic regression test. Only patients with complete data are included in the study.Results: There are 91 patients with complete data, 59 patients (64.83%) were patients without metastasis and 32 patients (35.16%) were with metastasis. There was significant statistical difference between no metastasis group with metastasis group for PSA (13.7ng/mL vs71.5ng/mL; p = 0.001), hemoglobin level (13.60 g/dL vs 12.25 g/dL; p = 0.002), and KPS (90vs90; p = 0.004). There was also significant statistical difference in GSS groups (35 and 24 in metastasis-free group vs 12 and 20 in metastasis group; p = 0.047). Age, prostate volume, tumor stadium, and creatinine level had no statistical difference between the two groups (p > 0.05). Pretreatment PSA value was the only predictive factor for metastasis with odds ratio 1.014 (95% CI, 1.005 to 1.022; p = 0.002).Conclusion: Most nonpalpable prostate cancer patients are first detected without metastasis. Pretreatment PSA value that was obtained at their initial visit might be used as predictive factor for metastasis for them in the future.;Objective: Prostate cancer incident is globally increasing. Despite early detection of prostate cancer, the progressivity of the disease itself toward metastatic disease remains different for each patient. The purpose of this study is to observe aspects that may have roles as predictive factors for metastasis in nonpalpable prostate cancer.Materials and Methods: Data was collected from National Hospital Cipto Mangunkusumo and Dharmais National Cancer Center Hospital from 1995-2013. Patients with nonpalpable prostate cancer then divided into two groups: metastasis-free group and metastasis group. Age, prostate volume, pretreatment Prostate-specific antigen (PSA) value, Gleason score sum group, tumor stadium, Karnofsky performance score (KPS), hemoglobin level, and serum creatinine level were factors that were analyzed in the study. The data was analyzed using bivariate analysis and logistic regression test. Only patients with complete data are included in the study.Results: There are 91 patients with complete data, 59 patients (64.83%) were patients without metastasis and 32 patients (35.16%) were with metastasis. There was significant statistical difference between no metastasis group with metastasis group for PSA (13.7ng/mL vs71.5ng/mL; p = 0.001), hemoglobin level (13.60 g/dL vs 12.25 g/dL; p = 0.002), and KPS (90vs90; p = 0.004). There was also significant statistical difference in GSS groups (35 and 24 in metastasis-free group vs 12 and 20 in metastasis group; p = 0.047). Age, prostate volume, tumor stadium, and creatinine level had no statistical difference between the two groups (p > 0.05). Pretreatment PSA value was the only predictive factor for metastasis with odds ratio 1.014 (95% CI, 1.005 to 1.022; p = 0.002).Conclusion: Most nonpalpable prostate cancer patients are first detected without metastasis. Pretreatment PSA value that was obtained at their initial visit might be used as predictive factor for metastasis for them in the future.;Objective: Prostate cancer incident is globally increasing. Despite early detection of prostate cancer, the progressivity of the disease itself toward metastatic disease remains different for each patient. The purpose of this study is to observe aspects that may have roles as predictive factors for metastasis in nonpalpable prostate cancer.Materials and Methods: Data was collected from National Hospital Cipto Mangunkusumo and Dharmais National Cancer Center Hospital from 1995-2013. Patients with nonpalpable prostate cancer then divided into two groups: metastasis-free group and metastasis group. Age, prostate volume, pretreatment Prostate-specific antigen (PSA) value, Gleason score sum group, tumor stadium, Karnofsky performance score (KPS), hemoglobin level, and serum creatinine level were factors that were analyzed in the study. The data was analyzed using bivariate analysis and logistic regression test. Only patients with complete data are included in the study.Results: There are 91 patients with complete data, 59 patients (64.83%) were patients without metastasis and 32 patients (35.16%) were with metastasis. There was significant statistical difference between no metastasis group with metastasis group for PSA (13.7ng/mL vs71.5ng/mL; p = 0.001), hemoglobin level (13.60 g/dL vs 12.25 g/dL; p = 0.002), and KPS (90vs90; p = 0.004). There was also significant statistical difference in GSS groups (35 and 24 in metastasis-free group vs 12 and 20 in metastasis group; p = 0.047). Age, prostate volume, tumor stadium, and creatinine level had no statistical difference between the two groups (p > 0.05). Pretreatment PSA value was the only predictive factor for metastasis with odds ratio 1.014 (95% CI, 1.005 to 1.022; p = 0.002).Conclusion: Most nonpalpable prostate cancer patients are first detected without metastasis. Pretreatment PSA value that was obtained at their initial visit might be used as predictive factor for metastasis for them in the future.;Objective: Prostate cancer incident is globally increasing. Despite early detection of prostate cancer, the progressivity of the disease itself toward metastatic disease remains different for each patient. The purpose of this study is to observe aspects that may have roles as predictive factors for metastasis in nonpalpable prostate cancer.Materials and Methods: Data was collected from National Hospital Cipto Mangunkusumo and Dharmais National Cancer Center Hospital from 1995-2013. Patients with nonpalpable prostate cancer then divided into two groups: metastasis-free group and metastasis group. Age, prostate volume, pretreatment Prostate-specific antigen (PSA) value, Gleason score sum group, tumor stadium, Karnofsky performance score (KPS), hemoglobin level, and serum creatinine level were factors that were analyzed in the study. The data was analyzed using bivariate analysis and logistic regression test. Only patients with complete data are included in the study.Results: There are 91 patients with complete data, 59 patients (64.83%) were patients without metastasis and 32 patients (35.16%) were with metastasis. There was significant statistical difference between no metastasis group with metastasis group for PSA (13.7ng/mL vs71.5ng/mL; p = 0.001), hemoglobin level (13.60 g/dL vs 12.25 g/dL; p = 0.002), and KPS (90vs90; p = 0.004). There was also significant statistical difference in GSS groups (35 and 24 in metastasis-free group vs 12 and 20 in metastasis group; p = 0.047). Age, prostate volume, tumor stadium, and creatinine level had no statistical difference between the two groups (p > 0.05). Pretreatment PSA value was the only predictive factor for metastasis with odds ratio 1.014 (95% CI, 1.005 to 1.022; p = 0.002).Conclusion: Most nonpalpable prostate cancer patients are first detected without metastasis. Pretreatment PSA value that was obtained at their initial visit might be used as predictive factor for metastasis for them in the future., Objective: Prostate cancer incident is globally increasing. Despite early detection of prostate cancer, the progressivity of the disease itself toward metastatic disease remains different for each patient. The purpose of this study is to observe aspects that may have roles as predictive factors for metastasis in nonpalpable prostate cancer.Materials and Methods: Data was collected from National Hospital Cipto Mangunkusumo and Dharmais National Cancer Center Hospital from 1995-2013. Patients with nonpalpable prostate cancer then divided into two groups: metastasis-free group and metastasis group. Age, prostate volume, pretreatment Prostate-specific antigen (PSA) value, Gleason score sum group, tumor stadium, Karnofsky performance score (KPS), hemoglobin level, and serum creatinine level were factors that were analyzed in the study. The data was analyzed using bivariate analysis and logistic regression test. Only patients with complete data are included in the study.Results: There are 91 patients with complete data, 59 patients (64.83%) were patients without metastasis and 32 patients (35.16%) were with metastasis. There was significant statistical difference between no metastasis group with metastasis group for PSA (13.7ng/mL vs71.5ng/mL; p = 0.001), hemoglobin level (13.60 g/dL vs 12.25 g/dL; p = 0.002), and KPS (90vs90; p = 0.004). There was also significant statistical difference in GSS groups (35 and 24 in metastasis-free group vs 12 and 20 in metastasis group; p = 0.047). Age, prostate volume, tumor stadium, and creatinine level had no statistical difference between the two groups (p > 0.05). Pretreatment PSA value was the only predictive factor for metastasis with odds ratio 1.014 (95% CI, 1.005 to 1.022; p = 0.002).Conclusion: Most nonpalpable prostate cancer patients are first detected without metastasis. Pretreatment PSA value that was obtained at their initial visit might be used as predictive factor for metastasis for them in the future.]"

"ABSTRAKNama : Ken Indra TProgram Studi : : Pendidikan Dokter Spesialis Obstetri dan GinekologiJudul : Prevalensi Occult metastasis pada omentum Pasien Kanker Ovarium Epitelial Stadium Awal Yang Menjalani Surgical staging di RSCM Tahun 2009 ndash; 2015TUJUAN: Mengetahui besarnya prevalensi occult metastasis kanker ovarium epitelial stadium klinis dini pada omentum yang dilakukan pembedahan di RSCM periode Januari 2009 ndash; Desember 2015.LATAR BELAKANG: Secara anatomis, omentum adalah lokasi utama penyebaran dari kanker ovarium epithelial. Hal ini ditunjukkan dari berbagai penelitian yang menyebutkan bahwa terdapat prevalensi metastasis yang tinggi ke omentum. Hal ini menyebabkan FIGO membuat rekomendasi untuk melakukan pembedahan sitoreduksi dan surgical staging yang teliti dan hati-hati pada kasus-kasus dengan kecurigaan kanker ovarium. Penelitian mengenai omentektomi dalam pembedahan kanker ovarium epithelial masih belum ada di Indonesia sehingga kami melakukan penelitian inilDESAIN DAN METODE: Penelitian ini menggunakan desain potong silang dengan mengambil rekam medis pasien kanker ovarium yang dilakukan pembedahan di RSCM pada bulan Januari 2009 ndash; Desember 2015.HASIL: Pada sebanyak 1 subjek dari 51 subjek penelitian 2 ditemukan occult metastasis pada omentum. Prevalensi metastasis pada kanker ovarium epithelial stadium dini pada tahun 2009 ndash; 2015 adalah sebesar 33,3 17 dari 51 subjek , dimana keterlibatan omentum ditemukan pada 2 subjek 1 dari 51 .KESIMPULAN: Prevalensi occult metastasis kanker ovarium epithelial stadium klinis dini yang dilakukan pembedahan di RSCM tahun 2009 ndash; 2015 adalah sebesar 2 1 dari 51 subjek Kata Kunci: Metastasis, Omentum, Karsinoma Ovarium, Epitelial, Prevalensi

---

ABSTRACTName Ken IndraStudy Program Obstetrics and GynecologyTitle Prevalence of occult omental metastases of early stage epithelial ovarian cancer patients whom had surgical staging in RSCM from 2009 ndash 2015. AIM To know the prevalence of occult metastases of epithelial ovarian cancer clinically early stage in RSCM.BACKGROUND Topographically, omentum is the main spread location of epithelial ovarian cancer. This is shown by various study showing that there is high incidences of metastases of ovarian cancer to the omentum. This made FIGO to produce a guideline to remove omentum in surgical staging of ovarian cancer. Omentectomy study in epithelial ovarian cancer surgery has not been performed in Indonesia, thus we made this study.DESIGN AND METHODOLOGY Cross sectional study. We collect data retrospectively from medical records of cases of epithelial ovarian cancer who were operated in RSCM from January 2009 ndash December 2015.RESULTS 1 out of 51 subjects 2 was found to have occult metastases in the omentum. The prevalence of metastases of epithelial ovarian cancer clinically early stage from 2009 ndash 2015 is 33.3 17 out of 51 subjects whereas the involvement of omentum was found in 2 1 out of 51 subjects .CONCLUSION The prevalence of occult omental metastases of ephitelial ovarian cancer clinically early stage in RSCM from 2009 ndash 2015 is 2 1 out of 51 subjects .Keywords Metastases, Omentum, Ovarian Cancer, Prevalence."

"ABSTRAKLatar Belakang Peningkatan insidensi tumor metastasis intrakranial setiap tahunnya, juga diikuti oleh meningkatnya angka disabilitas dan mortalitas pada pasien. Terapi standar pada tumor metastasis otak adalah WBRT, SRS, operasi atau kombinasi dari ketiganya. Dengan semua pilihan terapi yang ada, sangat penting untuk memerhatikan prognosis pasien dengan tumor metastasis otak untuk menentukan jenis terapi yang sesuai, salah satunya dengan menggunakan indeks prognosis. Belum terdapat data yang menggambarkan profil demografis dan kesintasan pasien tumor metastasis otak di Indonesia dengan menerapkan indeks prognosis yang sudah ada.Tujuan dan Metode Penelitian ini merupakan studi cohort retrospektif untuk melihat kesesuaian hasil analisis kesintasan pasien tumor metastasis otak di Departemen Radioterapi RSUPN Dr. Cipto Mangunkusumo tahun 2012-2014 dengan data acuan indeks RPA, GPA, dan BSBM.Hasil Terdapat 62 subyek yang diikutsertakan dalam penelitian ini setelah mendapat persetujuan. Median kesintasan keseluruhan mencapai 9,16 bulan. Hasil analisis kesintasan berdasarkan indeks RPA memperlihatkan median kesintasan Kelas I, Kelas II dan Kelas III, secara berurutan 16.3 bulan, 11.2 bulan, dan 4.7 bulan. Karakteristik dan median kesintasan subyek pengamatan berdasarkan indeks GPA, secara berurutan mulai dari GPA 0-1 sampai GPA 3,5-4 adalah 4.3, 10.4, 12.4, dan 16.3 bulan. Hasil penerapan kedua indeks tersebut terlihat sesuai dengan data acuan penelitian pendahulunya. Namun indeks BSBM tidak mampu memperlihatkan hasil yang sesuai saat diterapkan pada populasi sampel penelitian.Kesimpulan Indeks RPA dan GPA dapat digunakan untuk memprediksi prognosis pasien tumor metastasis otak di RSUPN-CM karena memberikan karakterisitik yang sesuai dengan data acuan. Indeks GPA dianggap lebih baik karena menggunakan variabel yang lebih objektif.

---

ABSTRACTBackground The incidence of intracranial metastasis has increased annually, which also followed by the increased number of patient rsquo s disability and mortality. Standard therapy in brain metastasis are Whole Brain Radiotherapy WBRT , Stereotactic Radio Surgery SRS , surgery, or combination of all. With all these treatment options available, it is very important to consider the prognosis in order to decide which therapy is appropriate. One of the methods that can be used to determine the prognosis is by using the prognostic indices. Currently, there has been no data or report about the demographic and survival profile of patients with brain metastastis in Indonesia using the available index prognosis.Methods This is a retrospective cohort study to evaluate the survival analysis in patients with brain metastasis that are undergoing treatment in Radiotherapy Department, RSUPN Dr. Cipto Mangunkusumo in 2012 2014 based on RPA, GPA, and BSBM index.Results Sixty two patients are included in this study after obtaining the approved consent. The median of survival rate is 9.16 months. Survival analysis based on RPA index showed median class I, II, and III are 16.3, 11.2, and 4.7 months, respectively. Characteristics and median observer based on GPA, from GPA 0 1 to GPA 3.5 4 are 4.3, 10.4, 12.4, and 16.3 months, respectively. These findings are similar with the previous studies. However, BSBM index does not able to illustrate the result that is appropriate when it is being applied to the subjects of this study.Conclusions RPA and GPA index can be used to predict the prognosis in patients with brain metastasis that are undergoing treatment in RSUPN Dr. Cipto Mangunkusumo because it provides characteristics, which correspond to the reference data. GPA index is considered better because it uses more objective variables."

"Latar Belakang : Metastasis tulang merupakan masalah pada pasien kanker paru karena memperburuk prognosis dan kualitashidup. Nyeri merupakan salah satugejala yang paling umum. Tatalaksana metastasis tulang pada pasien kanker paru meliputi terapi pada tumor primer, radioterapi pada lesi metastasis dan pemberian ibandronic acid.Metode : Penelitian ini merupakan studi retrospektif. Kami mencatat pasien kanker paru bermetastasis tulang dan dirawat di rumah sakit pusat rujukan respirasi nasional Persahabatan Jakarta dari tanggal 1 Januari 2016 sampai 30 Juni 2018. Tujuan penelitian ini untuk mengevaluasi penurunan nyeri kanker yang berhubungan dengan metastasis tulang. Semua pasien menerima terapi ibandronic acid 6 mg intravena setiap bulan dan diukur skala nyerinya dengan menggunakan Visual Analogue Scale (VAS). Selain mendapat terapi ibandronic acid, setiap pasien juga mendapatkan modalitas terapi nyeri kanker lain seperti analgetik, radioterapi atau kombinasi keduanya. Hasil : Lokasi lesi kanker paru bermetastasis ke tulang paling sering (dari 51/71 pasien) adalah vertebra 74 (43,79%), toraks 55 (32,54%) dan pelvis 28 (17,75%). Rerata jumlah pemberian ibandronic acid adalah 8 kali pemberian. Rentang waktu pemberian ibandronic acid dari tegak jenis adalah 6 bulan. Nyeri VAS setelah pemberian ibandronic acid berturut-turut nyeri VAS ringan (VAS 1-3) 14 (27,54%), nyeri VAS sedang (VAS 4-6) 37 (72,46%) dan nyeri berat (VAS 7-10) 0 (0%). Total waktu penurunan nyeri setelah pemberian ibandronic acid adalah 4 bulan. Rerata penurunan nyeri VAS pada grup nyeri VAS ringan-sedang terjadi setelah 5 kali pemberian sedangkan rerata penurunan grup nyeri VAS berat setelah 1 kali pemberian (p = 0.0001). Terdapat beberapa kejadian efek samping setelah pemberian ibandronic acid yang ditemukan pada 9 dari 51 subjek antara lain 2 (3,9%) ruam kulit, 3 (5,9%) mual dan muntah, 3 (5,9%) sakit kepala dan 1 (2,0%) demam.Kesimpulan : Terapi ibandronic acid sangat bermanfaat untuk menurunkan nyeri kanker pada pasien kanker paru bermetastasis ke tulang

---

Background: Bone metastasis (BM) is one of the problems in lung cancer because it affects the prognosis and quality of life. Pain is most common symptom. The management of bone metastasis (BM) in lung cancer are treatment of primary cancer lesion, radiotherapy on the metastatic lesions and ibandronic acid.

Method : In this retrospective study, lung cancer patients with BM and treated in Persahabatan National Respiratory Referral Hospital, Jakarta, between January 1st 2016 and June 30th 2018 were enrolled. The aim of study was to evaluate the efficacy of ibandronic acid in the treatment of cancer pain caused by BM. All of patients received ibandronic acid 6 mg (intravenously) monthly and Visual Analogue Scale (VAS) was used to evaluate pain. All patients received other management cancer pain such as analgesics, radiotherapy or combination.

Results : Most BM lesions (51/71 cases) were located in vertebra 74 (43,79%), thoracic cage 55( 32,54%) and pelvic 28 (17,75%). The averages of administration of ibandronic acid 6 mg iv was 8 times. The mean time-to-treat of ibandronic acid since the first time of lung cancer diagnosis was 6 months. VAS pain scale after administration of ibandronic acid was classified to mild pain (VAS 1-3) 14 cases (27,54%), moderate pain (VAS 4-6) 37 cases (72,46%) and severe pain (VAS 7-10) 0 cases. Overall the decrease in VAS scale was seen after 4 times ibandronic acid administration. Pain was significantly improved after the fifth administration in patients which initially suffered from moderate to mild pain and was significantly improved immediately after the first administration in patients which initially suffered from severe pain (p=0,0001). The side effects caused by ibandronic acid was observed in 9 patients, in which 2 subjects (3,9%) had a rash skin, 3 subjects (5,9%) suffered nausea and vomiting, 3 subjects (5,9%) had headache, and 1 subject (2,0%) fever.

Conclusion : Ibandronic acid treatment was useful to relieve metastatic bone pain in lung cancer patients."